Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerodalcibep vs Inclisiran in High Risk CVD Patients
NCT05004675Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of lerodalcibep in hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), sponsored by LIB Therapeutics. Started Jun 2022; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05004675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004675.